AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub
This article was originally published in The Pink Sheet Daily
Executive Summary
Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.
You may also be interested in...
Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS
Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.
Stronger Euro Could Make Bayer’s Full-Year Sales Target “Ambitious”
The German conglomerate highlights sales of its five new medicines that have gotten off to good starts in the marketplace and has identified another five early stage cardiology and oncology products to push through its pipeline.
Deals Of The Week: Wondering Where Have The Private Biotech Take-Outs Gone?
M&A has slowed for private biotechs this year, as acquisitions are overshadowed by IPOs. AstraZeneca is one of the few big biopharmas actively buying private biotechs. An option-to-acquire deal structure, amply employed by Celgene, is popping up lately.